134 related articles for article (PubMed ID: 32603315)
21. Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML.
Zhang Y; Jiang S; He F; Tian Y; Hu H; Gao L; Zhang L; Chen A; Hu Y; Fan L; Yang C; Zhou B; Liu D; Zhou Z; Su Y; Qin L; Wang Y; He H; Lu J; Xiao P; Hu S; Wang QF
Genome Biol; 2023 Aug; 24(1):199. PubMed ID: 37653425
[TBL] [Abstract][Full Text] [Related]
22. The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies.
Liu H; Peng J; Huang L; Ruan D; Li Y; Yuan F; Tu Z; Huang K; Zhu X
Front Immunol; 2023; 14():1154146. PubMed ID: 37398678
[TBL] [Abstract][Full Text] [Related]
23. CD103
van Hooren L; Handgraaf SM; Kloosterman DJ; Karimi E; van Mil LWHG; Gassama AA; Solsona BG; de Groot MHP; Brandsma D; Quail DF; Walsh LA; Borst GR; Akkari L
Nat Cancer; 2023 May; 4(5):665-681. PubMed ID: 37081259
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Hou X; Du H; Deng Y; Wang H; Liu J; Qiao J; Liu W; Shu X; Sun B; Liu Y
J Transl Med; 2023 Mar; 21(1):198. PubMed ID: 36927689
[TBL] [Abstract][Full Text] [Related]
25. Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding.
Maetzig T; Lieske A; Dörpmund N; Rothe M; Kleppa MJ; Dziadek V; Hassan JJ; Dahlke J; Borchert D; Schambach A
Cells; 2022 Dec; 11(24):. PubMed ID: 36552809
[TBL] [Abstract][Full Text] [Related]
26. Targeting FGL2 in glioma immunosuppression and malignant progression.
Ma X; Zhu H; Cheng L; Chen X; Shu K; Zhang S
Front Oncol; 2022; 12():1004700. PubMed ID: 36313679
[TBL] [Abstract][Full Text] [Related]
27. Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology.
Chen S; Jiang J; Shen A; Miao Y; Cao Y; Zhang Y; Cong P; Gao P
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295820
[TBL] [Abstract][Full Text] [Related]
28. Mastering the use of cellular barcoding to explore cancer heterogeneity.
Serrano A; Berthelet J; Naik SH; Merino D
Nat Rev Cancer; 2022 Nov; 22(11):609-624. PubMed ID: 35982229
[TBL] [Abstract][Full Text] [Related]
29. Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.
Shah PV; Arrieta VA; Lee-Chang C; Sonabend AM
J Cell Immunol; 2020; 2(6):352-358. PubMed ID: 35592772
[No Abstract] [Full Text] [Related]
30. Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities.
Andersen JK; Miletic H; Hossain JA
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267626
[TBL] [Abstract][Full Text] [Related]
31. A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.
Cai Y; Liang X; Zhan Z; Zeng Y; Lin J; Xu A; Xue S; Xu W; Chai P; Mao Y; Song Z; Han L; Xiao J; Song Y; Zhang X
Front Cell Dev Biol; 2021; 9():812422. PubMed ID: 35174170
[No Abstract] [Full Text] [Related]
32. Single-Molecule RNA Sequencing Reveals IFNγ-Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus-Positive MCC Cell Lines.
Sauerer T; Lischer C; Weich A; Berking C; Vera J; Dörrie J
Front Microbiol; 2021; 12():785662. PubMed ID: 35003017
[TBL] [Abstract][Full Text] [Related]
33. Tumor evolution selectively inactivates the core microRNA machinery for immune evasion.
Song TY; Long M; Zhao HX; Zou MW; Fan HJ; Liu Y; Geng CL; Song MF; Liu YF; Chen JY; Yang YL; Zhou WR; Huang DW; Peng B; Peng ZG; Cang Y
Nat Commun; 2021 Dec; 12(1):7003. PubMed ID: 34853298
[TBL] [Abstract][Full Text] [Related]
34. Phenotyping clonal populations of glioma stem cell reveals a high degree of plasticity in response to changes of microenvironment.
Innes JA; Lowe AS; Fonseca R; Aley N; El-Hassan T; Constantinou M; Lau J; Eddaoudi A; Marino S; Brandner S
Lab Invest; 2022 Feb; 102(2):172-184. PubMed ID: 34782726
[TBL] [Abstract][Full Text] [Related]
35. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
[TBL] [Abstract][Full Text] [Related]
36. Glial and myeloid heterogeneity in the brain tumour microenvironment.
Andersen BM; Faust Akl C; Wheeler MA; Chiocca EA; Reardon DA; Quintana FJ
Nat Rev Cancer; 2021 Dec; 21(12):786-802. PubMed ID: 34584243
[TBL] [Abstract][Full Text] [Related]
37. Genetic and non-genetic clonal diversity in cancer evolution.
Black JRM; McGranahan N
Nat Rev Cancer; 2021 Jun; 21(6):379-392. PubMed ID: 33727690
[TBL] [Abstract][Full Text] [Related]
38. Glioma escape signature and clonal development under immune pressure.
Maire CL; Mohme M; Bockmayr M; Fita KD; Riecken K; Börnigen D; Alawi M; Failla A; Kolbe K; Zapf S; Holz M; Neumann K; Dührsen L; Lange T; Fehse B; Westphal M; Lamszus K
J Clin Invest; 2020 Oct; 130(10):5257-5271. PubMed ID: 32603315
[TBL] [Abstract][Full Text] [Related]
39. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
40. Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting.
Appolloni I; Alessandrini F; Ceresa D; Marubbi D; Gambini E; Reverberi D; Loiacono F; Malatesta P
Cancer Lett; 2019 Feb; 442():213-221. PubMed ID: 30312732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
